Drug Discovery--European Advances in Genomics and Proteomics (Technical Insights)

 


This research service tracks, analyzes and profiles emerging technologies, especially genomics and proteomics for drug discovery in Europe

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

Drug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Executive SummaryIntroductionIntroductionGenomicsProteomicsPrimary Applications: Drug Discovery and Molecular DiagnosticsMarket TrendsScope and MethodologyScopeMethodologyDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Primer on Genomics and Proteomics TechnologiesGenomicsIntroductionSNP ProfilingFunctional GenomicsStructural GenomicsPharmacogenomicsToxicogenomicsChemical Genomics (Chemogenomics)ProteomicsIntroductionProteomics TechniquesRelated Fields of StudyGlycomics and Other “Omics”Systems BiologyDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Applications Analysis and TrendsGenomicsDrug DiscoveryMolecular DiagnosticsProteomicsDrug DiscoveryMolecular DiagnosticsAntibodies as TherapeuticsDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Noteworthy Innovation at Key Academic and Government-Related InstitutionsAnalysis and Ranking of Application SegmentsIntroductionRegulatory HurdlesGenomicsDNA ChipsHuman Epigenome ProjectProteomicsProtein ChipsGerman Research Foundation To Establish Seven New Research CentersDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Noteworthy Innovation by Key companiesGenomicsPharmacogenomicsGenome SequencingGene ExpressionReverse GenomicsFunctional GenomicsApplicationsLabeling and Detection MethodsDNA Chips and MicroarraysChemical GenomicsAdditional Genomics CompaniesProteomicsProtein CrystallographySpectroscopyAntibodies for Protein Identification; Auto-Immune ResearchDetection and LabelingProtein and Antibody Expression SystemsProtein-Protein InteractionProtein chipsApplicationsAdditional Proteomics CompaniesThe Other 'ics'GlycomicsBioinformaticsDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Regulatory and Political FactorsGovernment Guidelines and SupportFDA GuidelinesGovernmental Support; Both Financial and IP Protection; Are NeededPharmaceutical Industry ResponsePharmaceutical Industry ReluctanceFear of the NewDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Industry TrendsMarket TrendsGenomicsProteomics And Systems BiologyEnabling Technologies and Their MarketsElectrophoresis and Proteome InformaticsDNA and Protein MicroarraysSpectroscopy and ChromatographyLabs-on-a-Chip--Miniaturization Brings Higher Throughput with Less SampleMultiplexing and Biomarker-Based Diagnostics MarketAutomationNew Tools for GenomicsHigh-Throughput Screening Technologies Accelerate Drug DiscoveryDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Technology Adoption Factor AnalysisTechnology DriversTechnology Features and BenefitsAdoption Drivers for Genomics and ProteomicsAnalysis of FundingTechnology RestraintsTechnology or Product Development RestraintsCompeting Technologies and ComplexityDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Contacts and PatentsContactsEuropean CompaniesNon-European CompaniesPatentsPatents--Section I Patents-- Section IIDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Frost & Sullivan 2005 Science and Technology AwardsTechnology InnovationAward DescriptionAward RecipientTechnology LeadershipAward DescriptionAward RecipientProduct LeadershipAward DescriptionAward RecipientDrug Discovery--European Advances in Genomics and Proteomics (Technical Insights), Decision Support DatabaseDecision Support Database Relevant To This StudyGovernment Healthcare ExpenditurePrivate Healthcare ExpenditureTotal Healthcare ExpenditureGovernment Biotech R&D InvestmentsPrivate Biotech R&D InvestmentsPharma R&D Expenditure




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.